Find Funding Opportunities

This Funding Opportunity Announcement (FOA) encourages grant applications for the conduct of innovative, collaborative research projects between U.S. and low- and middle-income country (LMIC) scientists, on brain and other nervous system function and disorders throughout life, relevant to LMICs. Scientists in upper middle income countries (UMICs) are eligible to partner directly with scientists at other LMIC institutions. Income categories are defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-len… . The collaborative research programs are expected to contribute to the long-term goals of building sustainable research capacity in LMICs to address nervous system development, function and impairment throughout life and to lead to diagnostics, prevention, treatment and implementation strategies. The proposed work will also contribute to developing a base for research networking and evidence-based policy beyond the specific research project.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIH R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs and foster a better understanding of biomedical, behavioral and clinical research and its implications. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on developing courses for skills development, specifically, training modules for graduate students, postdoctoral fellows, and beginning investigators designed to enhance data reproducibility.

The purpose of this Funding Opportunity Announcement (FOA) is to publicize a competition for Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers (MDCRCs). These Centers promote collaborative basic, translational and clinical research and provide important resources that can be used by the national muscular dystrophy research communities. The centers also provide an outstanding environment for the training of new scientists electing to pursue careers conducting research in high priority areas of muscular dystrophy. Center investigators are expected to participate in important community outreach efforts to increase awareness and convey the importance and implications of their research activities to the patient and advocacy communities.

The goal of this funding opportunity announcement is to support interdisciplinary research that will lead to a greater understanding of the mechanisms by which vascular factors contribute to the complex etiology of Alzheimer's disease.

The purpose of this FOA is to solicit applications for an Epilepsy Center without Walls (CWOW) focused on multidisciplinary, collaborative research to further the development of disease modifying or prevention therapies for epilepsy.

This Funding Opportunity Announcement (FOA) encourages administrative supplements for the NINDS Research Education Program for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (R25, PAR-13-384, RFA-NS-10-002, RFA-NS-09-001)

This Funding Opportunity Announcement invites an application to create a Connectome Coordination Facility. The competition is limited to the U54 awardees of RFA-MH-10-020. The goal of this award is to (1) maintain a central data repository for Human Connectome data; (2) create a helpdesk service to answer questions from investigators who are trying to collect data that are compatible with the existing Human Connectome data; and (3) to serve, in a limited capacity, as a quality control for new data that are being deposited.

The purpose of this initiative is to detect, characterize and measure the progression of neurodegeneration in individuals with a probable or possible diagnosis of chronic traumatic encephalopathy (CTE) using brain imaging and other biomarkers. The overall goals are increased knowledge concerning the neurological mechanisms and ways to detect CTE as it evolves over a 3 - 5 year period and the development of a consensus diagnosis to inform clinical trials aimed at preventing or slowing disease progression in the future.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue translational and clinical studies for therapeutic devices to treat neurological disorders. The program will utilize a cooperative agreement mechanism to support the submission of an Investigational Device Exemption (IDE) or IRB approval for a Non-Significant Risk (NSR) study and the following clinical study. It is expected that the clinical study will inform a final device design that would have to go through most, if not all, of the preclinical testing on the path to more advanced clinical trials and market approval. This program also supports development of a device to test scientific hypotheses that are not feasible or practical to conduct in animal models, but are critical to enable next-generation devices. Activities supported in this program include implementation of clinical prototype devices, preclinical safety and efficacy testing, design verification and validation activities, pursuit of regulatory approval for the clinical study, and a small clinical study.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue translational and Early Feasibility Studies for therapeutic devices to treat neurological disorders. The program will utilize a cooperative agreement mechanism to support the submission of an Investigational Device Exemption (IDE), with the option of also supporting the following Early Feasibility Study. It is expected the immediate next steps upon completion of the Early Feasibility Study will be a full Feasibility Study and a Pivotal Trial in support of a PMA (Pre-Market Approval) or HDE (Humanitarian Device Exemption). Activities supported in this program include implementation of clinical prototype devices, preclinical safety and efficacy testing, design verification and validation activities, pursuit of regulatory approval for the clinical study, and an Early Feasibility Study.